AXL, a receptor tyrosine kinase, plays a crucial role in various physiological processes, including cell survival, proliferation, migration, and immune response modulation. Overexpression of AXL is associated with several cancers and is often linked to poor prognosis, making it a valuable target for cancer therapy.

AXL belongs to the TAM (Tyro3, AXL, and Mer) family of receptor tyrosine kinases. It is activated by its ligand, Gas6 (growth arrest-specific 6), leading to downstream signaling pathways such as PI3K/AKT, MAPK, and NF-κB, which promote tumor cell survival, proliferation, and metastasis. Inhibiting AXL can therefore disrupt these pathways and potentially reduce tumor growth and spread.

The development of bemcentinib biosimilars represents a significant advancement in targeted cancer therapy. By inhibiting AXL, bemcentinib can disrupt critical pathways involved in cancer progression and resistance, offering hope for improved treatment outcomes. The rigorous process of developing biosimilars ensures that they match the reference product's efficacy and safety, making them a viable and potentially more accessible option for patients.

https://www.kmdbioscience.com/product/YR1509.html